Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Jun 14
Show Filter
7:00am - 8:00am 60 mins
Registration and Coffee
8:00am - 8:15am 15 mins
Opening Remarks
8:15am - 8:45am 30 mins
Keynote Presentations
A Safe and Highly Efficient Universal Genome Targeting Approach for Treating SCID-X1 in Human Long-Term Hematopoietic Stem Cells
  • Mara Pavel-Dinu, PhD - Postdoctoral Scholar, Porteus Lab, Pediatrics Department Stanford University Medical Center, Stanford University
8:45am - 9:15am 30 mins
Keynote Presentations
Improvements in Clone Screening and Production for Monoclonal Antibodies in CHO-DG44
  • Elizabeth H. Scheideman - Scientist, Cell Line Development, Vaccine Production Program, NIH
9:15am - 10:00am 45 mins
Networking Refreshment Break
10:00am - 10:30am 30 mins
Cell Line & Host Cell Engineering Technologies
Best of Both Worlds: Engineering a Double-Knockout CHO Host
  • Eric Lee - Associate Scientist II, Cell Culture Development, Biogen
10:30am - 11:00am 30 mins
Cell Line & Host Cell Engineering Technologies
Proteomic and Phosphoproteomic Analysis of CHO Cell Productivity
  • Susan Sharfstein, PhD - Professor of Nanobioscience, College of Nanoscale Science and Engineering, SUNY Polytechnic Institute
11:00am - 11:30am 30 mins
Spotlight Presentation
Engineering the Next Generation of Biomanufacturing CHO Cells
  • Aleksandra Jaskot - Research Scientist II, Horizon Discovery

Aside from process improvements focussed on media and feed strategies the CHO host remains largely unchanged from that which was used thirty years ago. Here I will present Horizon Discovery’s approach to improving our GS knockout CHO K1 cell line using genome engineering approaches such as CRISPR screening and rAAV to provide FTO in biomanufacturing.

11:30am - 12:00pm 30 mins
High Throughput Platforms for Cell Line Development
Cumate-inducible CHO Platform for Stable Pool and Stable Clone Generation
  • Yves Durocher - Section Head, Mammalian Cell Expression - NRC Human Health Therapeutics Research Center, National Research Council Canada

We describe our CHO expression platform for the rapid production of various recombinant proteins. We use the cumate-inducible CHO expression system that allows the generation of stable and scalable pools expressing high levels of monoclonal antibodies or r-proteins in 2-3 weeks post-transfection. The pools are also used to derive stable and high-expressing CHO clones for manufacturing therapeutic candidates.

12:00pm - 1:00pm 60 mins
High Throughput Platforms for Cell Line Development
1:00pm - 1:30pm 30 mins
High Throughput Platforms for Cell Line Development
Automated Cell Line Development to Increase Efficiency
  • David Shaw, Ph.D. - Senior Scientist, Early Stage Cell Culture, Genentech, Inc.

David Shaw*, Ali AlBarakat, Daniel Tran, Joni Tsukuda, Mandy Yim

Early Stage Cell Culture, Pharma Technical Development, Genentech, Inc.


Keywords:  cell line development automation, clonally-derived, single-cell printer

In order to increase efficiency, consistency and flexibility, we embarked on completely automating the clinical and commercial cell line development (CLD) process using custom automated solutions.  Automated single-cell cloning (SCC) and hit-picking workflows have been in use for several years and automate the most tedious steps in CLD.  The SCC workflow uses plate imaging to document that our cell lines are clonally-derived.  We added single-cell deposition to our plate imaging workflow to gain significant efficiencies over limiting dilution SCC.  We use existing hit-picking automation to pick and scale-up single-cell clones from 384-well plates to 96-well plates, 24-well plates, 6-well plates and 24-well deep well blocks.  We developed custom seed train automation to passage seed train cultures and set-up and sample fed-batch cultures in an unattended operation.  Using the same seed train automation and custom consumables we are able to scale up to 300mL cultures in an automated operation.  The implementation of the entire automated CLD workflow and our projected capacity of 50 – 200 cell lines per year with a very limited staff will be discussed. 

1:30pm - 2:00pm 30 mins
High Throughput Platforms for Cell Line Development
High stringency selection of high producer CHO cells using a metabolic selection marker
  • Mark Trautwein - Senior Scientist, Bayer AG - Pharmaceuticals Division

The concept of high stringency selection of cells producing high amounts of a desired protein of interest is well known in the art and different solutions exist. However, many existing solutions exhibit different drawbacks e.g. need to engineer a host cell line or use of an antibiotic. The presentation will introduce a high stringency selection system using an endogenous metabolic selection marker without the need for cell line engineering.

2:00pm - 2:15pm 15 mins
High Throughput Platforms for Cell Line Development
Networking Refreshment Break
2:15pm - 2:45pm 30 mins
High Throughput Platforms for Cell Line Development
Approaches to increasing cell line development throughput
  • Rob Ballinger - Development Associate III, Alexion
2:45pm - 3:15pm 30 mins
Omics in Cell Line
Knowledge Based Multi-omics Integration and Systems Analysis of CHO Cells or Next Generation Cell Line Development
  • Dong-Yup Lee - Assistant Professor / Senior Scientist, Chemical and Biomolecular Engineering, National University of Singapore / Bioprocessing Technology Institute
3:15pm - 3:45pm 30 mins
Improving HIV Vaccine Production: Gene Editing and Robotic Cell Selection to Improve Upstream and Downstream
  • Phillip Berman, PhD - Distinguished Professor, Biomolecular Engineering, University of California Santa Cruz

Currently there is a logjam of candidate HIV vaccines awaiting clinical testing .  HIV subunit vaccines have been more difficult to manufacture than other biopharmaceuticals due to extensive heterogeneity in N-linked glycosylation.  Here we describe the use of gene editing and robotic selection to create an MGAT1- CHO cell line that improves upstream and downstream manufacturing processes.

3:45pm - 3:50pm 5 mins
End of Conference